# EDGAR Filing Document

**Accession Number:** 0001637715
**File Stem:** 0001193125-26-104215
**Filing Date:** 2026-3
**Character Count:** 20241
**Document Hash:** a47337da4723b8172d7bf9a39c62072b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-104215.hdr.sgml**: 20260312

**ACCESSION NUMBER**: 0001193125-26-104215

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 15

**FILED AS OF DATE**: 20260312

**DATE AS OF CHANGE**: 20260312

**EFFECTIVENESS DATE**: 20260312

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** OnKure Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001637715
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 472309515
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-294248
- **FILM NUMBER:** 26748101

**BUSINESS ADDRESS:**
- **STREET 1:** 6707 WINCHESTER CIRCLE, SUITE 400
- **CITY:** BOULDER
- **STATE:** CO
- **ZIP:** 80301
- **BUSINESS PHONE:** (720) 307-2892

**MAIL ADDRESS:**
- **STREET 1:** 6707 WINCHESTER CIRCLE, SUITE 400
- **CITY:** BOULDER
- **STATE:** CO
- **ZIP:** 80301

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Reneo Pharmaceuticals, Inc.
- **DATE OF NAME CHANGE:** 20150325

**As filed with the Securities and Exchange Commission on March 12, 2026** 

**Registration No. 333-** 

------

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

------

**FORM S-8** 

**REGISTRATION STATEMENT** 

***UNDER*** 

***THE SECURITIES ACT OF 1933*** 

------

**ONKURE THERAPEUTICS, INC.** 

**(Exact name of registrant as specified in its charter)** 

------

---

| | |
|:---|:---|
| **Delaware** | **47-2309515** |
| **(State or other jurisdiction of**<br>**incorporation or organization)** | **(I.R.S. Employer**<br>**Identification No.)** |

---

---

| |
|:---|
| **6707 Winchester Circle, Suite 400<br>Boulder, Colorado 80301** |
| **(Address of Principal Executive Offices, including zip code)** |

---

**OnKure Therapeutics, Inc. 2024 Equity Incentive Plan<br>OnKure Therapeutics, Inc. 2024 Employee Stock Purchase Plan**

(Full title of the plan)

**Nicholas A. Saccomano<br>President and Chief Executive Officer<br>6707 Winchester Circle, Suite 400**

**Boulder, CO 80301**

**(720) 307-2892** 

(Name, address and telephone number, including area code, of agent for service)

***Copies to:*** 

**Tony Jeffries**

**Jennifer Knapp**

**Phillip McGill**

**Wilson Sonsini Goodrich & Rosati, P.C.**

**1155 Canyon Blvd., Suite 400**

**Boulder, CO 80302**

**(303) 256-5900** 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
|  |  | Emerging growth company | ☒ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

------

**EXPLANATORY NOTE**

This Registration Statement on Form S-8 (the "Registration Statement") is filed by OnKure Therapeutics, Inc. (the "Registrant") for the purpose of registering (i) 683,678 additional shares of Class A common stock, par value $0.0001 per share (the "Class A Common Stock") of the Registrant reserved for issuance under the 2024 Equity Incentive Plan (the "2024 Plan"), pursuant to the provision of the 2024 Plan providing for an automatic increase in the number of shares reserved for issuance under the 2024 Plan, and (ii) 136,735 additional shares of Class A Common Stock of the Registrant reserved for issuance under the 2024 Employee Stock Purchase Plan (the "2024 ESPP"), pursuant to the provision of the 2024 ESPP providing for an automatic increase in the number of shares reserved for issuance under the 2024 ESPP.

**PART II<br>INFORMATION REQUIRED IN REGISTRATION STATEMENT**

**Item 3. Incorporation of Documents by Reference.**

The Registrant previously registered shares of its Class A Common Stock for issuance under the 2024 Plan and the 2024 ESPP on Registration Statements on Form S-8 filed by the Registrant with the Securities and Exchange Commission (the "SEC") on [<u>December 9, 2024</u>](https://www.sec.gov/Archives/edgar/data/1637715/000095017024134582/okur_s-8_20241209_no_xbr.htm) (File No. 333-283693) and [<u>March 10, 2025</u>](https://www.sec.gov/Archives/edgar/data/1637715/000095017025036363/okur_s-8_20250310_no_xbr.htm) (Files No. 333-285680) (the "Previous Forms S-8"). Accordingly, pursuant to General Instruction E of Form S-8, this Registration Statement hereby incorporates by reference the contents of the Previous Forms S-8, including the information incorporated by reference therein and the periodic reports filed after the Previous Forms S-8 to maintain current information about the Registrant, except as set forth below.

The following documents filed by the Registrant with the SEC are incorporated by reference into this Registration Statement:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.[<u>The Registrant's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the SEC on March 12, 2026 (File No. 001-40315)</u>](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001637715/000119312526104147/okur-20251231.htm);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.All other reports filed with the SEC pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), since the end of the fiscal year covered by the Registrant's Annual Report referred to in (1) above, only to the extent that the items therein are specifically stated to be "filed" rather than "furnished" for the purposes of the Exchange Act; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.The description of the Registrant's Class A Common Stock contained in the Registrant's Registration Statement on Form 8-A filed with the SEC on [<u>April 6, 2021</u>](https://www.sec.gov/Archives/edgar/data/1637715/000119312521107604/d168698d8a12b.htm) pursuant to Section 12(b) of the Exchange Act, as updated by [<u>Exhibit 4.2</u>](https://www.sec.gov/Archives/edgar/data/1637715/000119312526104147/okur-ex4_2.htm) to the Registrant's Annual Report on Form 10-K filed with the SEC on March 12, 2026, including any amendment or report filed for the purpose of updating such description.

All other reports or documents filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement that indicates that all securities offered have been sold or that deregisters all securities then remaining unsold shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of filing of such documents, shall be deemed to be incorporated by reference herein and to be a part of this registration statement from the date of filing such reports and documents; *provided*, *however*, that reports, documents and information, or portions thereof, deemed to have been furnished and not filed in accordance with the rules of the SEC shall not be deemed incorporated by reference into this Registration Statement. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be

------

modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document which also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

**Item 8. Exhibits.**

The Registrant has filed the exhibits listed on the accompanying Exhibit Index of this Registration Statement.

**EXHIBIT INDEX** 

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| &nbsp;&nbsp;**Exhibit<br>Number** | &nbsp;&nbsp;**Exhibit Description** | &nbsp;&nbsp;**Incorporated by Reference** | &nbsp;&nbsp;**Incorporated by Reference** | &nbsp;&nbsp;**Incorporated by Reference** | &nbsp;&nbsp;**Incorporated by Reference** |
| &nbsp;&nbsp;**Exhibit<br>Number** | &nbsp;&nbsp;**Exhibit Description** | &nbsp;&nbsp;**Form** | &nbsp;&nbsp;**File No.** | &nbsp;&nbsp;**Exhibit** | &nbsp;&nbsp;**Filing Date** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.1 | &nbsp;&nbsp;[<u>Amended and Restated Certificate of Incorporation, as amended, of OnKure Therapeutics, Inc</u>](https://www.sec.gov/Archives/edgar/data/1637715/000119312524234487/d836681dex32.htm). | &nbsp;&nbsp;8-K | &nbsp;&nbsp;001-40315 | &nbsp;&nbsp;3.2 | &nbsp;&nbsp;October 8, 2024 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.2 | &nbsp;&nbsp;[<u>Amended and Restated Bylaws of OnKure Therapeutics, Inc</u>](https://www.sec.gov/Archives/edgar/data/1637715/000119312524234487/d836681dex33.htm). | &nbsp;&nbsp;8-K | &nbsp;&nbsp;001-40315 | &nbsp;&nbsp;3.3 | &nbsp;&nbsp;October 8, 2024 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.3 | &nbsp;&nbsp;[<u>2024 Equity Incentive Plan and forms of agreement thereunder</u>](https://www.sec.gov/Archives/edgar/data/1637715/000119312524234487/d836681dex1014.htm). | &nbsp;&nbsp;8-K | &nbsp;&nbsp;001-40315 | &nbsp;&nbsp;10.14 | &nbsp;&nbsp;October 8, 2024 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.4 | &nbsp;&nbsp;[<u>2024 Employee Stock Purchase Plan</u>](https://www.sec.gov/Archives/edgar/data/1637715/000119312524234487/d836681dex1015.htm) | &nbsp;&nbsp;8-K | &nbsp;&nbsp;001-40315 | &nbsp;&nbsp;10.15 | &nbsp;&nbsp;October 8, 2024 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.1 | &nbsp;&nbsp;[<u>Opinion of Wilson Sonsini Goodrich & Rosati, P.C.</u>](okur-ex5_1.htm) |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;23.1 | &nbsp;&nbsp;[<u>Consent of KPMG LLP, independent registered public accounting firm</u>](okur-ex23_1.htm). |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;23.2 | &nbsp;&nbsp;[<u>Consent of Wilson Sonsini Goodrich & Rosati, P.C. (included in Exhibit 5.1 hereto)</u>](okur-ex5_1.htm). |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;24.1 | &nbsp;&nbsp;[<u>Power of Attorney (included on the signature page hereto).</u>](#poa) |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;107 | &nbsp;&nbsp;[<u>Filing Fee Table</u>](okur_exfilingfees.htm) |  |  |  |  |

---

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Boulder, State of Colorado, on March 12, 2026.

---

| | |
|:---|:---|
| **ONKURE THERAPEUTICS, INC.** | **ONKURE THERAPEUTICS, INC.** |
| By: | /s/ Nicholas A. Saccomano |
|  | Nicholas A. Saccomano |
|  | President and Chief Executive Officer |

---

**POWER OF ATTORNEY** 

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Nicholas A. Saccomano and Jason Leverone, and each of them, as his or her true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for such person in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments) on Form S-8, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact, proxy, and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said attorney-in-fact, proxy and agent, or any substitute of any of them, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated:

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /s/ Nicholas A. Saccomano<br>Nicholas A. Saccomano | Chief Executive Officer, President and Director<br>(*Principal Executive Officer*) | March 12, 2026 |
| /s/ Jason Leverone<br>Jason Leverone | Chief Financial Officer<br>(*Principal Financial and Accounting Officer*) | March 12, 2026<br>|
| /s/ R. Michael Carruthers<br>R. Michael Carruthers | Director | March 12, 2026<br>|
| /s/ Michael Grey<br>Michael Grey | Director | March 12, 2026<br>|
| /s/ Valerie M. Jansen<br>Valerie M. Jansen | Director | March 12, 2026<br>|
| /s/ Isaac Manke<br>Isaac Manke | Director | March 12, 2026<br>|

---

---

| | | |
|:---|:---|:---|
| /s/ Edward T. Mathers | Director | March 12, 2026 |
| Edward T. Mathers |  |  |
| /s/ Andrew Phillips | Chairman | March 12, 2026 |
| Andrew Phillips |  |  |

---

------

## Exhibit 5.1

&nbsp;&nbsp;**Exhibit 5.1**<br>

---

| | |
|:---|:---|
| ![img201043379_0.jpg](img201043379_0.jpg) | Wilson Sonsini Goodrich & Rosati<br>Professional Corporation<br>650 Page Mill Road<br>Palo Alto, California 94304-1050<br>o: (650) 493-9300<br> f: (650) 493-6811 |

---

March 12, 2026

OnKure Therapeutics, Inc.

6707 Winchester Circle, Suite 400

Boulder, CO 80301

**Re: Registration Statement on Form S-8**

Ladies and Gentlemen:

At your request, we have examined the Registration Statement on Form S-8 (the "**Registration Statement**") to be filed by OnKure Therapeutics, Inc., a Delaware corporation (the "**Company**"), with the Securities and Exchange Commission (the "**Commission**") on or about the date hereof, relating to the registration under the Securities Act of 1933, as amended (the "**Act**"), of shares of your Class A common stock, par value $0.0001 per share (the "**Shares**"), consisting of: (i) 683,678 shares of Class A common stock to be issued under the Company's 2024 Equity Incentive Plan (the "**2024 Plan**") and (ii) 136,735 shares of Class A common stock to be issued under the Company's 2024 Employee Stock Purchase Plan (the "**2024 ESPP**" and, together with the 2024 Plan, the "**Plans**"). As your legal counsel, we have reviewed the actions proposed to be taken by you in connection with the issuance and sale of the Shares to be issued under the Plans.

On the basis of the foregoing, and in reliance thereon, we are of the opinion that the Shares, when issued and sold in the manner described in the Plans and pursuant to the agreements that accompany the Plans, will be legally and validly issued, fully paid and nonassessable.

We hereby consent to the filing of this opinion as an exhibit to the above-referenced Registration Statement and to the use of our name wherever it appears in the Registration Statement and in any amendments thereto. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Act or the rules and regulations of the Commission thereunder.

---

| |
|:---|
| Very truly yours, |
| **WILSON SONSINI GOODRICH & ROSATI** |
| Professional Corporation  |
| /s/ Wilson Sonsini Goodrich & Rosati, P.C. |

---

austin boston BOULDER brussels hong kong london los angeles new york palo alto<br>SALT LAKE CITY san diego san francisco seattle shanghai washington, dc wilmington, de

------

## Exhibit 23.1

**Exhibit 23.1**

Consent of Independent Registered Public Accounting Firm

<br>We consent to the use of our report dated March 12, 2026, with respect to the consolidated financial statements of OnKure Therapeutics, Inc., incorporated herein by reference.

/s/ KPMG LLP

Denver, Colorado

March 12, 2026

------

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

 **Exhibit 107**

**Calculation of** Filing Fee **Tables**

**Form** S-8

(Form Type)

OnKure Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

**Table 1 - Newly Registered Securities**

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | Security Type | **Security Class Title** | **Fee<br>Calculation<br>Rule** | **Amount Registered** | **Proposed<br>Maximum<br>Offering<br>Price Per<br>Unit** | **Maximum Aggregate<br>Offering Price** | **Fee Rate** | **Amount of<br>Registration<br>Fee** |
| (1) | Equity | Class A Common Stock, par value $0.0001 per share, reserved for issuance under the Registrant's 2024 Equity Incentive Plan | Other | 683678 | $3.15 | $2153585.70 | 0.0001381 | $297.41 |
| (2) | Equity | Class A Common Stock, par value $0.0001 per share, reserved for issuance under the Registrant's 2024 Employee Stock Purchase Plan | Other | 136735 | $2.68 | $366449.80 | 0.0001381 | $50.61 |
|  | **Total Offering Amounts** | **Total Offering Amounts** | **Total Offering Amounts** | 820413 |  | $2520035.50 |  | $348.02 |
|  | **Total Fee Offsets** | **Total Fee Offsets** | **Total Fee Offsets** | **Total Fee Offsets** |  |  |  | $- |
|  | **Net Fee Due** | **Net Fee Due** | **Net Fee Due** | **Net Fee Due** |  |  |  | $348.02 |

---

(1)Pursuant to Rule 416(a) of the Securities Act of 1933, as amended (the "**Securities Act**"), this Registration Statement on Form S-8 ("**Registration Statement**") covers any additional shares of OnKure Therapeutics, Inc.'s (the "**Registrant**") Class A common stock that become issuable under the Registrant's 2024 Equity Incentive Plan (the "**2024 Plan**") by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without the Registrant's receipt of consideration which results in an increase in the number of the outstanding shares of Class A common stock. The amount registered represents an automatic increase to the number of shares of the Registrant's Class A common stock reserved for issuance pursuant to future awards under the 2024 Plan, which annual increase is provided for in the 2024 Plan. The proposed maximum offer price is estimated in accordance with Rule 457(c) and (h) of the Securities Act solely for the purpose of calculating the registration fee on the basis of $[3.15] per share, which is the average of the high and low prices of the Registrant's Class A common stock, as reported on the Nasdaq Global Market, on March [6], 2026.

(2)Pursuant to Rule 416(a) of the Securities Act, this Registration Statement covers any additional shares of the Registrant's Class A common stock that become issuable under the Registrant's 2024 Employee Stock Purchase Plan (the "**2024 ESPP**") by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without the Registrant's receipt of consideration which results in an increase in the number of the outstanding shares of Class A common stock. The amount registered represents an automatic increase to the number of shares of the Registrant's Class A common stock reserved for issuance under the 2024 ESPP, which annual increase is provided for in the 2024 ESPP. The proposed maximum offer price is estimated in accordance with Rule 457(c) and (h) of the Securities Act solely for the purpose of calculating the registration fee on the basis of 85% of $[3.15] per share, which is the average of the high and low prices of the Registrant's Class A common stock, as reported on the Nasdaq Global Market, on March [6], 2026. Pursuant to the 2024 ESPP, the purchase price of the shares of the Registrant's Class A common stock reserved for issuance thereunder will be at least 85% of the lower of the fair market value of the Registrant's Class A common stock on the enrollment date or on the exercise date.

------